Search filters
 Trial Filters
Clear All

Phase

  • 3
  • 1
  • 1
  • 5
  • 4
  • 1
  • 5

Solid Tumor Clinical Trials

A listing of Solid Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 5 clinical trials
SAR408701 in Patients With CEACAM5-positive Advanced Solid Tumors

Primary Objective: -To assess the antitumor activity of SAR408701 in metastatic breast cancer (mBC) and metastatic pancreatic adenocarcinoma (mPAC) Secondary Objective: To assess the safety and tolerability of SAR408701 To assess other efficacy parameters of SAR408701 To assess the immunogenicity of SAR408701

Phase 2
Learn more
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Primary Objectives: Dose Escalation: To determine maximum tolerated dose (MTD) or maximum administered dose (MAD) and overall safety and tolerability profile of SAR441000 when administered intratumorally as monotherapy and in combination with cemiplimab in patients who have no alternative standard treatment options. Dose Expansion (Combination): To determine the objective response …

Phase 1
Learn more
Safety and Efficacy Study of SAR442720 in Combination With Pembrolizumab in Advanced Malignancies

Primary Objective: Part 1: To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in patients with advanced solid tumors including NSCLC who progressed on anti-PD-1/PD L1 containing therapy and advanced colorectal cancer (CRC) after progression to all standard of care (SOC) therapy. To define the MTD and …

Phase 1
Learn more
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors

Primary Objectives: Part 1 (Dose Escalation) To determine the MTD/maximum administered dose (MAD) of SAR443216 administered as a single agent in participants with HER2 expressing solid tumors and determine the RP2D in the dose escalation part. To determine the maximum lead-in dose and the recommended target dose for phase 2. …

Phase 1
Learn more
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors

Primary Objectives: Evaluate the safety and tolerability of THOR-707 as a single agent and as a combination therapy (identify Dose Limiting Toxcitiy (DLTs), Adverse Events (AEs)/serious adverse event (SAE) profile) Define the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) of THOR-707 as a single agent and …

Phase 1/2
Learn more